Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP

Adaptimmune Therapeutics (ADAP) Stock Forecast & Price Target

542 Followers
See the Price Targets and Ratings of:

ADAP Analyst Ratings

Moderate Buy
6Ratings
3 Buy
3 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Adaptimmune
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ADAP Stock 12 Months Forecast

Average Price Target

$5.25
▲(159.90% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Adaptimmune Therapeutics in the last 3 months. The average price target is $5.25 with a high forecast of $10.00 and a low forecast of $1.50. The average price target represents a 159.90% change from the last price of $2.02.
Highest Price Target$10.00Average Price Target$5.25Lowest Price Target$1.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Barclays
$2.00
Sell
-0.99%
Downside
Reiterated
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (NASDAQ: ADAP) and Sigilon Therapeutics (NASDAQ: SGTX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ADAP Financial Forecast

ADAP Earnings Forecast
Next quarter’s earnings estimate for ADAP is -$0.24 with a range of -$0.27 to -$0.20. The previous quarter’s EPS was -$0.25. ADAP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.38% of the time in the same period. In the last calendar year ADAP has Underperformed its overall industry.
Next quarter’s earnings estimate for ADAP is -$0.24 with a range of -$0.27 to -$0.20. The previous quarter’s EPS was -$0.25. ADAP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.38% of the time in the same period. In the last calendar year ADAP has Underperformed its overall industry.
ADAP Sales Forecast
Next quarter’s sales forecast for ADAP is $9.21M with a range of $500.00K to $35.00M. The previous quarter’s sales results were $6.95M. ADAP beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 42.94% of the time in the same period. In the last calendar year ADAP has Outperformed its overall industry.
Next quarter’s sales forecast for ADAP is $9.21M with a range of $500.00K to $35.00M. The previous quarter’s sales results were $6.95M. ADAP beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 42.94% of the time in the same period. In the last calendar year ADAP has Outperformed its overall industry.
ADAP Analyst Recommendation Trends
In the current month, ADAP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ADAP average analyst price target in the past 3 months is $5.25
In the current month, ADAP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ADAP average analyst price target in the past 3 months is $5.25

ADAP Stock Forecast FAQ

What is ADAP’s average 12-month price target, according to analysts?
Based on analyst ratings, Adaptimmune Therapeutics’s 12-month average price target is $5.25.
    What is ADAP’s upside potential, based on the analysts’ average price target?
    Adaptimmune Therapeutics has 159.90% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ADAP a Buy, Sell or Hold?
          Adaptimmune Therapeutics has a conensus rating of Moderate Buy which is based on 3 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Adaptimmune Therapeutics’s price target?
            The average price target for Adaptimmune Therapeutics is $5.25. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $1.50. The average price target represents 159.90% Increase from the current price of $2.02.
              What do analysts say about Adaptimmune Therapeutics?
              Adaptimmune Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis